Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Tetrylammonium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | ATM | Q13315 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 0.89 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.89 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.89 |
| ▸ | DNM1 | Q05193 | 4/20 | 0.39 |
| ▸ | SLC22A1 | O15245 | 3/20 | 0.36 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrylammonium SCHEMBL10982449 | 1.00 | KDM4E (1.00) | KDM4EPMP22ATMTSHRNFKB1 | |
| Tetrylammonium SCHEMBL49847 | 1.00 | KDM4E (1.00) | KDM4EPMP22ATMTSHRNFKB1 | |
| Tetrylammonium SCHEMBL9183225 | 0.95 | KDM4E (0.90) | KDM4EPMP22ATMTSHRNFKB1 | |
| Tetrylammonium SCHEMBL6560332 | 0.95 | KDM4E (0.90) | KDM4EPMP22ATMTSHRNFKB1 | |
| Tetrylammonium SCHEMBL11589433 | 0.95 | KDM4E (0.90) | KDM4EPMP22ATMTSHRNFKB1 | |
| Tetrylammonium SCHEMBL9183233 | 0.95 | KDM4E (0.90) | KDM4EPMP22ATMTSHRNFKB1 | |
| Tetrylammonium SCHEMBL5374887 | 0.95 | KDM4E (0.90) | KDM4EPMP22ATMTSHRNFKB1 | |
| Tetrylammonium SCHEMBL228998 | 0.95 | KDM4E (0.90) | KDM4EPMP22ATMTSHRNFKB1 | |
| Tetrylammonium SCHEMBL22664597 | 0.95 | KDM4E (0.90) | KDM4EPMP22ATMTSHRNFKB1 | |
| Tetrylammonium SCHEMBL9183220 | 0.95 | KDM4E (0.90) | KDM4EPMP22ATMTSHRNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188006-A1 | 13C-LABELLED CHLORINATED PARAFFINS AND THEIR PREPARATION | CHIRON AS (NO) | 2025-06-12 | — | — | US | claimed |
| EP-4493530-A1 | 13 C-LABELLED CHLORINATED PARAFFINS AND THEIR PREPARATION | Chiron AS (NO) | 2025-01-22 | — | — | EP | claimed |
| WO-2023174709-A1 | 13C-LABELLED CHLORINATED PARAFFINS AND THEIR PREPARATION | CHIRON AS (NO) | 2023-09-21 | — | — | WO | claimed |
| EP-4245742-A1 | 13C-LABELLED CHLORINATED PARAFFINS AND THEIR PREPARATION | Chiron AS (NO) | 2023-09-20 | — | — | EP | claimed |
| US-3997362-A | AMMONIUM | EXXON RESEARCH AND ENGINEERING COMPANY (US) | 1976-12-14 | — | — | US | claimed |
| EP-3507316-B1 | HALOGEN AND POLYHALIDE MEDIATED PHENOLIC POLYMERIZATION | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4617325-A1 | QUINACRIDONE COMPOUND | DIC Corporation (JP) | 2025-09-17 | — | — | EP | disclosed |
| EP-4617326-A1 | DIKETOPYRROLOPYRROLE COMPOUND | DIC Corporation (JP) | 2025-09-17 | — | — | EP | disclosed |
| US-20250188006-A1 | 13C-LABELLED CHLORINATED PARAFFINS AND THEIR PREPARATION | CHIRON AS (NO) | 2025-06-12 | — | — | US | disclosed |
| CN-119907833-A | Pyrrolopyrroldione compounds | DIC株式会社 | 2025-04-29 | — | — | CN | disclosed |
| CN-119604587-A | Quinacridone compounds | DIC株式会社 | 2025-03-11 | — | — | CN | disclosed |
| EP-4493530-A1 | 13 C-LABELLED CHLORINATED PARAFFINS AND THEIR PREPARATION | Chiron AS (NO) | 2025-01-22 | — | — | EP | disclosed |
| US-6528664-B2 | Synthetic methods for polyphenols | MARS, INCORPORATED | 2003-03-04 | — | — | US | disclosed |
| EP-1027345-B1 | SYNTHETIC METHODS FOR POLYPHENOLS | MARS INC (US) | 2003-02-19 | — | — | EP | disclosed |
| US-20020128493-A1 | Coupling flavonoid-like compounds having protected hydroxy groups by functionalizing the C-4; oxidative dehydrogenation to form dimers and oligomers; efficiency; anticarciogenic agents; breast cancer | MARS, INCORPORATED | 2002-09-12 | — | — | US | disclosed |
| US-6420572-B1 | FLAVANOID DERIVATIVES AND PHENOLIC DERIVATIVES WITH HALOGENATION | MARS, INCORPORATED | 2002-07-16 | — | — | US | disclosed |
| US-6242609-B1 | AMMONIUM TRIHALIDE FOR HALOGENATION OF COLOR COUPLERS AND SILVER HALIDE EMULSIONS | KONICA CORPORATION (JP) | 2001-06-05 | — | — | US | disclosed |
| EP-1027345-A1 | SYNTHETIC METHODS FOR POLYPHENOLS | Mars Incorporated (US) | 2000-08-16 | — | — | EP | disclosed |
| WO-1999019319-A1 | SYNTHETIC METHODS FOR POLYPHENOLS | MARS INCORPORATED (US) | 1999-04-22 | — | — | WO | disclosed |
| US-3997362-A | AMMONIUM | EXXON RESEARCH AND ENGINEERING COMPANY (US) | 1976-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128493-A1 | Coupling flavonoid-like compounds having protected hydroxy groups by functionalizing the C-4; oxidative dehydrogenation to form dimers and oligomers; efficiency; anticarciogenic agents; breast cancer | GPX4, NOX4, TPD52L2 | KDM4E 1217/4885PMP22 4726/4885ATM 4487/4885 |
| US-20250188006-A1 | 13C-LABELLED CHLORINATED PARAFFINS AND THEIR PREPARATION | PCNA, CAT, CDC73 | KDM4E 785/4885PMP22 289/4885ATM 2328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.